WAT

Waters Corporation 10-Q Summary

Business Context and Reporting Period

This filing is a Quarterly Report on Form 10-Q for the period ended April 3, 2004. Waters Corporation designs, manufactures, and services analytical instruments, primarily High Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) systems, as well as thermal analysis and rheometry instruments. The company recently expanded into the laboratory informatics market through the acquisitions of Creon Lab Control AG (July 2003) and NuGenesis Technologies Corporation (February 2004).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total sales increased 15% year-over-year. Product sales rose 11% to $186.2 million, while service sales surged 31% to $68.9 million, driven by an expanding installed base and new acquisitions.
• Product Mix: HPLC sales grew approximately 16% (excluding currency), and Laboratory Informatics contributed $5.0 million in new revenue. Conversely, Mass Spectrometry sales declined approximately 16% (excluding the impact of a prior divestiture), with significant drops in European and Japanese markets.
• Profitability: Net income increased 20% to $40.8 million. The effective tax rate decreased to 20.0% from 22.2%, largely due to the tax effects of litigation and restructuring charges.
• Debt and Liquidity: Total borrowings increased significantly to $342.0 million (up from $221.3 million in the prior year) primarily to fund a $400 million share repurchase program. Despite higher debt, cash and cash equivalents grew by $51.8 million during the quarter.

Guidance, Outlook, and Risks

• Acquisitions: The company acquired NuGenesis for approximately $43.0 million in cash in February 2004. Pro forma results suggest the acquisition would have increased net income to $38.0 million for the quarter.
• Restructuring: A new restructuring initiative in January 2004 involved terminating 70 employees with a provision of $2.1 million. Simultaneously, the company reversed $2.0 million in accruals from a 2002 restructuring plan due to changes in facility closure plans.
• Litigation:
  • Applera Settlement: The company settled long-standing patent litigation with Applera Corporation (MDS/Sciex) for a one-time payment of $18.1 million, resolving claims in the U.S., U.K., Canada, and Japan.
  • Hewlett-Packard (HP): The company recorded a $7.8 million provision for estimated damages and fees related to ongoing patent infringement suits in England and France. A trial on damages is scheduled for November 2004.
• Capital Allocation: The company continues an aggressive share repurchase program, buying back 2,150 shares for $80.6 million in the quarter. No dividends are planned in the foreseeable future.

Investor Verification Checklist

• Mass Spectrometry Decline: Verify the sustainability of the 16% decline in MS sales and the impact of the U.S. market growth offsetting international losses.
• HP Litigation Exposure: Monitor the November 2004 damages trial regarding HP patent infringement and the potential for additional provisions beyond the current $7.8 million accrual.
• Debt Servicing: Assess the impact of increased debt levels ($342 million) on future interest expenses and liquidity, particularly given the reliance on borrowings to fund share buybacks.
• Acquisition Integration: Evaluate the performance of the new Laboratory Informatics segment (NuGenesis and Creon) and its contribution to future margins.
• Share Repurchase Impact: Confirm the remaining capacity under the $400 million buyback authorization and its effect on future earnings per share.